So far, the trial has exceeded this goal, with about 60% of the enrolled patients having cancers other than colon, rectal, breast, non-small cell lung, or prostate.Patients who might be eligible to enroll in a MATCH treatment arm will be identified by a participating gene sequencing lab through their usual genomic testing of patients’ tumors as part of their cancer care.As the trial progresses, new clinical sites will be added.Patients, families, and clinicians can also contact NCI’s Cancer Information Service to learn more about the COMET study.Patients will not need a new tumor biopsy to take part in this trial.Participating labs include: Foundation Medicine, Inc. and Caris Life Sciences will identify potential MATCH participants from the large numbers of cancer patients whose tumors they currently test from about 1,100 hospitals and clinics that are taking part in the MATCH trial.Genomic sequencing is a laboratory method that is used to determine the genetic makeup of cancer cells.
Participants will not be paid to take part in this study.
To learn more about MATCH, patients should start by speaking with their doctors or healthcare team.
More details about MATCH are available in the protocol summary.
The NCTN includes researchers, physicians, and health care professionals at public and private institutions across the United States.
They conduct clinical trials on all types of adult cancers.
NCI-MATCH, also known as MATCH, is a precision medicine cancer treatment clinical trial.